Ruben Tommasi

Chief Scientific Officer

Vivatides Therapeutics Inc.

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ruben Tommasi serves as the Chief Scientific Officer at Entasis Therapeutics, Inc, located in the United States. His research areas focus on the discovery and development of pathogen-targeted antibiotics, with an emphasis on β-lactamase inhibitors. Recent publications highlight his work on the pharmacokinetics and pharmacodynamics of antibiotics aimed at combating multi-drug-resistant infections.

Articles (3)

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Samir Moussa

UNITED STATES

View details

Sarah McLeod

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ruben Tommasi

Research Interests

Explore related searches

Contact this professor

About

Articles (3)

Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics

In Vitro Characterization of ETX1317, a Broad-Spectrum β-Lactamase Inhibitor That Restores and Enhances β-Lactam Activity against Multi-Drug-Resistant Enterobacteriales, Including Carbapenem-Resistant Strains

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282

Collaborators (2)

Samir Moussa

Sarah McLeod

Make your next move.